Related Experiment Videos
Treating depression in Alzheimer's disease: integration of differing guidelines
International Psychogeriatrics
|November 18, 2000
Summary
Selective serotonin reuptake inhibitors are recommended for treating depression in Alzheimer's disease (AD) patients, according to a review of psychiatric and neurology guidelines. This approach addresses key behavioral disturbances in AD management.
Area of Science:
- Neurology
- Psychiatry
- Pharmacology
Background:
- Alzheimer's disease (AD) research has advanced, yet behavioral symptoms cause significant patient and family distress.
- Management of these behavioral disturbances in AD remains controversial and not fully understood.
Purpose of the Study:
- To compare and integrate treatment guidelines for depression in Alzheimer's disease (AD).
- Analysis focuses on recommendations from the American Psychiatric Association and the American Academy of Neurology.
Main Methods:
- Comparative analysis of two major guideline publications on AD management.
- Focus on pharmacological treatments for depression in AD patients.
- Evaluation of data sources, generalizability, and conflicting recommendations.
Main Results:
- Selective serotonin reuptake inhibitors (SSRIs) are identified as a primary pharmacological option.
- Guidelines offer common and conflicting recommendations for depression management in AD.
Conclusions:
- SSRIs are the preferred pharmacotherapy for depression in Alzheimer's disease (AD).
- Further clarification on management strategies for behavioral disturbances in AD is warranted.